By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French firms Hybrigenics and Servier today announced a licensing and research deal targeting deubiquitinating enzymes, or DUBs, for various diseases that could result in the development of companion diagnostics.

Under the terms of the deal, Hybrigenics will identify and validate new targets among DUBs for cancer, diseases in neurology, psychiatry, rheumatology, and ophthalmology, as well as diabetes, and cardiovascular illness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.